NFE2L2 and diabetic kidney disease: However, the use of the Nrf2 activator bardoxolone methyl for the treatment of diabetic nephropathy was associated with the serious complications of heart failure and fluid retention in a clinical trial, which led to its premature termination, and suggests that Nrf2 activation in CKD may have detrimental effects [9].